SURPASS-CVOT Trial Results: Implications for Mounjaro's Cardiovascular Safety and FDA Labeling

Key Takeaways

• Main news: The SURPASS-CVOT trial demonstrated that tirzepatide (Mounjaro) is non-inferior to dulaglutide (Trulicity) in reducing major adverse cardiovascular events (MACE-3) in adults with Type 2 Diabetes and established Cardiovascular Disease, supporting its cardiovascular safety profile.
• Clinical impact: The SURPASS-CVOT trial showed tirzepatide achieved non-inferiority to dulaglutide in reducing MACE-3 in adults with Type 2 Diabetes and established Cardiovascular Disease.
• Market implications: Demonstrating non-inferiority to dulaglutide positions tirzepatide competitively in the T2DM market, potentially expanding its use among patients with cardiovascular comorbidities.
• Next steps: The tirzepatide cardiovascular safety data may influence Mounjaro's market positioning and potential Type 2 Diabetes treatment guidelines.

The SURPASS-CVOT trial has provided crucial data supporting the cardiovascular safety of tirzepatide (Mounjaro), a dual GIP and GLP-1 receptor agonist, in adults with type 2 diabetes and established atherosclerotic cardiovascular disease, potentially impacting future Type 2 Diabetes treatment guidelines and the FDA Mounjaro approval label. The trial demonstrated that tirzepatide is non-inferior to dulaglutide (Trulicity) in reducing major adverse cardiovascular events (MACE-3). Why it matters: This finding reinforces the drug's safety profile, potentially increasing its use among patients with both type 2 diabetes and cardiovascular comorbidities.

Drug Overview

Tirzepatide (Mounjaro) is a peptide-based medication functioning as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is indicated for the treatment of Type 2 Diabetes.

Clinical Insights

The SURPASS-CVOT trial, a Phase III study, evaluated the cardiovascular safety of tirzepatide in adults with type 2 diabetes and established atherosclerotic Cardiovascular Disease. The primary endpoint was the time to the first occurrence of MACE-3, defined as cardiovascular death, myocardial infarction, and stroke. Tirzepatide demonstrated non-inferiority to dulaglutide in reducing MACE-3 in this high-risk population. No new safety signals or adverse events were reported regarding tirzepatide's cardiovascular safety.

Regulatory Context

The SURPASS-CVOT trial results provide additional data to support the existing FDA Mounjaro approval and may inform future labeling updates. The trial confirms the cardiovascular safety profile of tirzepatide, which could potentially lead to an enhanced FDA Mounjaro cardiovascular safety label, reflecting a reduced cardiovascular risk. The FDA may consider these findings when reviewing any supplemental applications related to cardiovascular risk reduction. No new safety signals or adverse event data were reported regarding tirzepatide's cardiovascular safety.

Market Impact

The demonstration of non-inferiority to dulaglutide positions tirzepatide competitively in the Type 2 Diabetes market, particularly among patients with cardiovascular comorbidities. By showcasing comparable cardiovascular safety to an established GLP-1 receptor agonist, tirzepatide may see increased adoption by prescribers. Compared with dulaglutide, tirzepatide differentiates itself through its dual GIP and GLP-1 receptor agonism, offering a novel mechanism with comparable cardiovascular safety. The SURPASS-CVOT trial results enhance the drug's safety profile, potentially leading to a more favorable FDA label and increased market acceptance.

Future Outlook

Future clinical research may include ongoing cardiovascular outcome trials and real-world evidence studies to further evaluate the long-term cardiovascular effects of tirzepatide. An enhanced cardiovascular safety label could positively affect Mounjaro’s commercial uptake and competitive landscape. What to watch next: Continued monitoring of real-world data and potential label expansions will be crucial in assessing the long-term impact of tirzepatide on cardiovascular outcomes and market dynamics.

Frequently Asked Questions

References

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-29.

Dr. Sarah Chen MD, PhD, FACP

Senior Medical Editor

Dr. Sarah Chen is a board-certified internist and former FDA clinical reviewer with 15+ years of experience in pharmaceutical regulatory affairs. She received her MD from Johns Hopkins and her PhD in ...

📅 Published: April 29, 2026